Mohamed El Kassas1, Mohamed Alboraie2, Dalia Omran3, Mohamed Salaheldin4, Mohamed Naguib Wifi5, Mohamed ElBadry6, Adel El Tahan7, Sameera Ezzat8, Enass Moaz8, Amir M Farid4, Heba Omar3, Mahmoud Abouelkhair3, Shimaa Afify9, Kadry Elsaeed10, Yehia Shazly10, Wahid Doss3, Gamal Esmat3. 1. a Endemic Medicine Department, Faculty of Medicine , Helwan University , Cairo , Egypt. 2. b Department of Internal Medicine , Al-Azhar University , Cairo , Egypt. 3. c Endemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine , Cairo University , Cairo , Egypt. 4. d Tropical Medicine Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt. 5. e Internal Medicine Department, Faculty of Medicine , Cairo University , Cairo , Egypt. 6. f Tropical Medicine and Gastroenterology Department, Faculty of Medicine , Aswan University , Aswan , Egypt. 7. g New Cairo Viral Hepatitis Treatment Unit , Cairo , Egypt. 8. h Epidemiology and Preventive Medicine Department , National Liver Institute, Menoufia University , Shebin Elkom , Egypt. 9. i National Hepatology and Tropical Medicine Research Institute , Cairo , Egypt. 10. j Internal Medicine Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt.
Abstract
BACKGROUND: A large Egyptian treatment program for HCV was launched in2014 after the introduction of direct-acting antiviral agents (DAAs). This program depended mainly on establishing specialized independent centres for HCV treatment. These centres represent the major strengths in the Egyptian model of care, as they provide integrated care for HCV patients and have enabled Egypt to treat more than one million patients in 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example of these specialized centres. METHODS: The Egyptian experience in the management of HCV was evaluated by analysing the data of real-life HCV management in the NCVHTC from 2014 to 2017. Results of different treatment regimens in addition to their strengths, limitations and areas for improvement are discussed in this report. RESULTS: A total of 7042 HCV patients have been evaluated for treatment in the NCVHTC. Among them, 5517 patients received treatment by seven different DAA regimens with excellent results. CONCLUSIONS: All regimens were highly effective at treating HCV in a real-life setting, apart from SOF/RBV, which was the least effective. A nationwide screening program and enhancing the follow-up of treated patients are the main missing pillars in the Egyptian model.
BACKGROUND: A large Egyptian treatment program for HCV was launched in2014 after the introduction of direct-acting antiviral agents (DAAs). This program depended mainly on establishing specialized independent centres for HCV treatment. These centres represent the major strengths in the Egyptian model of care, as they provide integrated care for HCV patients and have enabled Egypt to treat more than one million patients in 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example of these specialized centres. METHODS: The Egyptian experience in the management of HCV was evaluated by analysing the data of real-life HCV management in the NCVHTC from 2014 to 2017. Results of different treatment regimens in addition to their strengths, limitations and areas for improvement are discussed in this report. RESULTS: A total of 7042 HCV patients have been evaluated for treatment in the NCVHTC. Among them, 5517 patients received treatment by seven different DAA regimens with excellent results. CONCLUSIONS: All regimens were highly effective at treating HCV in a real-life setting, apart from SOF/RBV, which was the least effective. A nationwide screening program and enhancing the follow-up of treated patients are the main missing pillars in the Egyptian model.
Entities:
Keywords:
DAAs; Egypt; HCV; model of care; real-life